Faderl S - Search Results

1

Shift of immunoglobulin phenotypes in B-cell precursor cell lines.

Faderl S, Estrov Z. Faderl S, et al. Leuk Res. 2002 Jan;26(1):11-2. doi: 10.1016/s0145-2126(01)00089-3. Leuk Res. 2002. PMID: 11734298

2

CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.

Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO, Pierce S, O'Brien S, Faderl S, Kantarjian HM. Ravandi F, et al. Among authors: faderl s. Leuk Res. 2002 Jul;26(7):643-9. doi: 10.1016/s0145-2126(01)00188-6. Leuk Res. 2002. PMID: 12008081

3

Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission.

Faderl S, Thall PF, Kantarjian HM, Estrov Z. Faderl S, et al. Br J Haematol. 2002 Jun;117(4):869-74. doi: 10.1046/j.1365-2141.2002.03506.x. Br J Haematol. 2002. PMID: 12060122 Free article.

4

The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.

Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O'Brien S, Albitar M. Ferrajoli A, et al. Among authors: faderl s. Blood. 2002 Aug 15;100(4):1215-9. Blood. 2002. PMID: 12149200 Free article.

5

Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.

Apostolidou E, Estey E, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Tsimberidou A, Kantarjian H, Giles FJ. Apostolidou E, et al. Among authors: faderl s. Leuk Res. 2003 Apr;27(4):301-4. doi: 10.1016/s0145-2126(02)00171-6. Leuk Res. 2003. PMID: 12531220 Clinical Trial.

6

N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).

Faderl S, Lotan R, Kantarjian HM, Harris D, Van Q, Estrov Z. Faderl S, et al. Leuk Res. 2003 Mar;27(3):259-66. doi: 10.1016/s0145-2126(02)00162-5. Leuk Res. 2003. PMID: 12537979

7

Commentary: effect of flavonoids on normal and leukemic cells.

Faderl S, Estrov Z. Faderl S, et al. Leuk Res. 2003 Jun;27(6):471-3. doi: 10.1016/s0145-2126(02)00276-x. Leuk Res. 2003. PMID: 12648504

8

Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.

Estey E, Giles F, Cortes J, Beran M, Verstovsek S, Garcia-Manero G, Faderl S, Kantarjian H. Estey E, et al. Among authors: faderl s. Leuk Res. 2003 Jun;27(6):475-9. doi: 10.1016/s0145-2126(03)00031-6. Leuk Res. 2003. PMID: 12648505

9

Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia.

Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M, Estrov Z. Faderl S, et al. Blood. 2003 Jul 15;102(2):630-7. doi: 10.1182/blood-2002-06-1890. Epub 2003 Mar 27. Blood. 2003. PMID: 12663443 Free article.

10

Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.

Verstovsek S, Lunin S, Kantarjian H, Manshouri T, Faderl S, Cortes J, Giles F, Albitar M. Verstovsek S, et al. Among authors: faderl s. Leuk Res. 2003 Jul;27(7):661-9. doi: 10.1016/s0145-2126(02)00275-8. Leuk Res. 2003. PMID: 12681367

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

387 results

Search Page

Filters